We work across key viral vector delivery systems including adeno-associated virus (AAV) to provide innovative solutions to cell and gene therapy biotechnology and biopharma companies.
We have built a sector leading lentiviral delivery system, LentiVector® platform which is already used in commercially available treatments.
Discover Oxford Biomedica - a leading gene and cell therapy with over 25 years of experience.
Get in touch
27 January 2023
Our viral vector platform is enabling our customers to bring next generation treatments for serious diseases to market.
OXB is an innovative leading viral vector specialist – Lenti, AAV, Adeno and beyond - focused on delivering life changing therapies to patients.